aCIDES-Department of Science Information and Decision Making in Health, Faculty of Medicine bCINTESIS-Center for Research in Health Technologies and Information Systems, Faculty of Medicine cGastroenterology Department, Portuguese Oncology Institute of Porto, Porto dGastroenterology Department, Portuguese Oncology Institute - Coimbra, Coimbra, Portugal.
Eur J Gastroenterol Hepatol. 2014 Apr;26(4):378-87. doi: 10.1097/MEG.0000000000000065.
Several reports of estimates for precancerous conditions for gastric adenocarcinoma can be found in the current literature. Our aim was to systematically review and estimate the prevalence of gastric precancerous conditions. Four databases (PubMed, Scopus, Web of Knowledge and EBSCO Academic Search Complete) were searched for original manuscripts addressing the presence of chronic atrophic gastritis (CAG) or intestinal metaplasia (IM). Subgroup analysis was carried out on methods of diagnosis, type of population, incidence of gastric cancer, sex, Helicobacter pylori status, age and extent of conditions. Overall, 107 studies were included. The worldwide prevalence of CAG in the general population was 33% (95% confidence interval: 26-41%) when considering biopsies (n=20 912) and 24% (19-29%) if serology (n=51 886) was used, whereas IM was found in 25% (19-30%) (n=30 960). Estimates for CAG were higher in countries with a high incidence of gastric cancer (42 vs. 23%), men (32 vs. 28%), H. pylori positive (46 vs. 17%) and if aged 40 years or older (48 vs. 22%). The prevalence of extensive conditions was 16% (12-20%) for CAG and 13% (9.0-17%) for IM. When comparing countries with high versus low to moderate incidence of gastric cancer, significant differences were achieved for CAG: 27% (12-36%) versus 7.3% (5.6-9.0%). Worldwide, one-third and one-fourth of individuals may harbour CAG and IM, respectively. In countries with a high incidence of gastric cancer, the prevalence of extensive conditions may increase up to 27% and these patients represent a high-risk population to whom endoscopic surveillance should be offered according to recent guidelines.
目前的文献中有几份关于胃腺癌癌前病变估计的报告。我们的目的是系统地回顾和估计胃癌前病变的流行率。我们在四个数据库(PubMed、Scopus、Web of Knowledge 和 EBSCO Academic Search Complete)中搜索了探讨慢性萎缩性胃炎(CAG)或肠上皮化生(IM)存在情况的原始手稿。对诊断方法、人群类型、胃癌发生率、性别、幽门螺杆菌状态、年龄和病变范围进行了亚组分析。总共纳入了 107 项研究。考虑到活检(n=20912),全球普通人群 CAG 的总体患病率为 33%(95%置信区间:26-41%),如果使用血清学(n=51886),则为 24%(19-29%),而 IM 的发现率为 25%(19-30%)(n=30960)。胃癌发病率高的国家(42%对 23%)、男性(32%对 28%)、幽门螺杆菌阳性(46%对 17%)和年龄在 40 岁或以上(48%对 22%)的 CAG 估计值更高。CAG 的广泛病变患病率为 16%(12-20%),IM 为 13%(9.0-17%)。在比较胃癌发病率高与低至中度的国家时,CAG 存在显著差异:27%(12-36%)对 7.3%(5.6-9.0%)。全球范围内,三分之一和四分之一的人可能分别患有 CAG 和 IM。在胃癌发病率高的国家,广泛病变的患病率可能增加到 27%,这些患者代表了一个高危人群,根据最近的指南,应该向他们提供内镜监测。